Prescribing quality improvement: reducing high-dose antipsychotic use

Asta R. Prajapati, Esther Johnston, Uju Ugochukwu, Bohdan Solomka

    Research output: Contribution to journalArticlepeer-review

    13 Downloads (Pure)

    Abstract

    Evidence of efficacy for high‐dose antipsychotic therapy (HDAT) and antipsychotic combinations (AC) is lacking, while evidence of harm is compelling. Significantly higher proportions of Norfolk and Suffolk NHS Foundation Trust (NSFT) patients were being prescribed HDAT and AC compared with the national averages. Here, the authors describe a quality improvement program to rationalise and reduce HDAT and AC prescribing in NSFT, to bring it in line with, or below, the national average. The initiative demonstrates that prescribing culture can be improved through a sustained multi‐professional team approach involving education and training, a targeted campaign, a proactive clinical pharmacy team and pharmacists' support.
    Original languageEnglish
    Pages (from-to)18-21
    Number of pages4
    JournalProgress in Neurology and Psychiatry
    Volume21
    Issue number3
    DOIs
    Publication statusPublished - 31 Aug 2017

    Cite this